SILVER SPRING, Md., July 23, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today continued to take action in the ongoing response to the COVID-19 pandemic:
Today, the FDA updated the Testing Supply Substitution Strategies slide show. This presentation includes validated supply alternatives that labs can use to continue performing testing when there is a supply issue with some components of a molecular test. Download the 1.5MB PowerPoint slide show file and click Slide Show > From Beginning.
This week, FDA and the Federal Trade Commission issued a joint warning letter to 21st Century LaserMed Pain & Regenerative Medicine Institute (d/b/a Create Wellness Clinics) for offering unapproved, unlicensed, uncleared and unauthorized products for the mitigation, prevention, treatment, diagnosis or cure of COVID-19. There are currently no FDA-approved products to prevent or treat COVID-19. Consumers concerned about COVID-19 should consult with their health care provider.
Testing updates:
To date, the FDA has currently authorized 187 tests under EUAs; these include 154 molecular tests, 31 antibody tests, and 2 antigen tests.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Tangibly, Inc., the leading SaaS trade secret management platform, today announced the launch of its consulting services offering. Designed to complement its trade secret software, the services are in response from customer feedback and requests for...
GradGuard, the number one provider of college tuition and renters insurance programs, is pleased to announce that it has expanded its tuition insurance protection to include the covered loss of employment of a tuition payer as a covered reason for...
Strategic collaboration to leverage Chiesi's legacy of respiratory leadership and Gossamer Bio's development expertise in pulmonary hypertension.Gossamer to receive $160 million development reimbursement payment and eligible to receive up to $146...
BMNT, a leader in government innovation, is strengthening its role in bridging commercial technology with national security through the promotion of two key team members. BMNT CEO Peter Newell announced that William Treseder has been appointed the...
SafeLogic today announced the launch of an Early Access Program (EAP) for its next-generation cryptographic software modules that include comprehensive support for all the PQC algorithms NIST is planning to standardize in the summer of 2024....
Regulatory News:
Timeline®, a pioneering Swiss consumer biotech company at the forefront of longevity research, is proud to announce the successful completion of its landmark immune aging clinical study, MitoImmune, using Mitopure (proprietary...